Loading company…
Okomera develops automated 3D organoid screening technology for cancer drug discovery.
Founded in 2020 and based in Paris, France, Okomera develops automated 3D organoid screening technology to assess drug responses. Its platform supports tests including CRISPR, T-cell, and cytotoxicity assessments, and can screen over 100 conditions per batch. In December 2023, it raised EUR 10.2 million in seed funding led by Resonance, with participation from the Ministry of Health and Welfare, Bpifrance, Berkeley SkyDeck Fund, and Polytechnique Ventures. The company has a US presence and planned to develop its cancer treatment response prediction technology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in